The Company
Timeline & Milestones
BioXcellerator did not appear overnight. What follows is a record of deliberate, compounding execution — from a single clinic in Medellín to a vertically integrated regenerative medicine platform with proprietary products, dual ISO certifications, GCP-compliant clinical infrastructure, and a growing intellectual property portfolio.
2015 — 2026
For investors evaluating BioXcellerator, this timeline is not a marketing narrative — it is a record of cumulative de-risking. Each year added new infrastructure, scientific depth, product advancement, quality certifications, and commercial traction. The result is a platform that has already absorbed the hardest costs of building a scalable regenerative medicine company.
Milestones are organized by year and categorized by type: infrastructure, certification and quality, research and regulatory, product launches, and revenue. Click any milestone to read the full investor-grade context. The 2026 milestones are planned and clearly marked as such.
Revenue Progression
Commercial TractionBioXcellerator has been generating revenue throughout its platform buildout — not after it. The progression below reflects a business commercializing in parallel with its scientific and operational development.
2026 figure is a forward-looking projection and does not represent a guarantee of future results.
BioXcellerator Founded — Medellín, Colombia
Eric Stoffers and Dr. Karolynn Halpert establish BioXcellerator with a clear thesis: build the world's most rigorous, vertically integrated regenerative medicine platform.
GCP Framework Established
First proprietary treatment protocols developed. Good Clinical Practices compliance framework established — setting a standard no competitor in the space had yet matched.
INVIMA & Ministry of Health Certifications · Medellín Clinic Buildout
Scientific protocol development underway. Regulatory certifications completed with INVIMA and the Colombian Ministry of Health. Flagship Medellín clinic constructed and opened.
Normoxic Wharton Jelly MSC Product
Development of normoxic Wharton jelly mesenchymal stem cell product — BioXcellerator's first proprietary cell therapy offering.
International Referral Network Established
International patient referral network established. First HCP partnerships formed, creating a distribution channel that would scale to 40+ U.S. healthcare providers.
10,000 Treatments Milestone
10,000 treatments milestone reached. Medical tourism model validated with documented outcomes across orthopedics, neurology, and autoimmune conditions.
ISO Certification Achieved
ISO certification achieved — formal quality management system validated across clinical operations. A major step from foundational infrastructure to operational maturity.
Clinical-Grade GMP-Compliant Facilities
Establishment of clinical-grade GMP-compliant facilities and laboratory cell bank consultation research group.
$6M Revenue — Pandemic Year
$6M revenue despite global pandemic disruption. Remote consultation model launched, demonstrating platform resilience.
New Clinic Facilities & GCP Certification
Expanded clinic facilities and Good Clinical Practices (GCP) certification — institutional-grade clinical execution environment.
BioX Innovations Vault Incorporated
BioX Innovations Vault, Inc. incorporated to formalize the IP portfolio and create the legal structure for commercialization.
Revenue Milestone — 2021
Commercial traction milestone. [Revenue figure to be confirmed by team]
Creation of the BioX Science Hub
BioX Science Hub established — a dedicated internal scientific and translational research engine.
$18M Revenue · 97% Patient Satisfaction
Revenue reaches $18M with 97% patient satisfaction — validating the clinical protocol library and referral network.
BioXcellerator ISO Certification
BioXcellerator achieves ISO certification — quality management system validated at the healthcare services platform level.
Quantum MU53 Cells — Hypoxic WJ-MSC Product
Launch of Quantum MU53 Cells — a proprietary hypoxic Wharton jelly mesenchymal stem cell product representing a decade of manufacturing and clinical expertise.
50,000 Treatments · 13 Publications
50,000 total treatments milestone. 13 published scientific works — establishing BioXcellerator as a credible contributor to the peer-reviewed evidence base.
BioX Tech ISO Certification
BioX Tech achieves ISO certification — manufacturing platform quality validated independently from BioXcellerator's 2023 certification.
Utah SB 199 Signed into Law
Utah SB 199 signed into law — a landmark regulatory development creating a legal pathway for advanced cell therapies in the United States.
66 IP Assets · 1,500+ Protocols
IP portfolio reaches 66 assets. 1,500+ proprietary protocols documented — a defensible operational moat.
$22M Revenue · BioX Tech ISO Year
Revenue reaches $22M in 2024 — the year BioX Tech achieves ISO certification, confirming quality management across both the clinical and manufacturing divisions.
BioX Science Recognized by Regulatory Board
BioX Science research group receives formal recognition from a regulatory board — institutional validation of the scientific platform.
New Products: WJ-MSC Cells & Secretome
Expansion of the product portfolio with Wharton jelly mesenchymal stem cells and secretome — broadening the therapeutic and commercial platform.
$22.9M Revenue · 85% Gross Margins
Revenue reaches $22.9M with 85% gross margins — among the highest in the sector, driven by vertical integration.
Utah Super Center Development Begins
Utah Super Center development begins. CDMO partnerships initiated — creating a new high-margin revenue stream.
Peptide Products Launch (Planned)
Planned launch of peptide products — expanding the therapeutic portfolio into a high-demand, scalable product category.
BioX Tech GMP Certification (Planned)
Planned GMP certification for BioX Tech manufacturing — the next level of manufacturing quality and regulatory readiness.
Production Scale-Up (Planned)
Planned production scale-up — expanding manufacturing capacity to support commercial growth and CDMO partnerships.
$25M+ Revenue Target — 2026 (Planned)
Revenue target of $25M+ for 2026, driven by Utah Super Center opening, CDMO partnerships, and BioX Health Longevity Center expansion.
Planned 2026 milestones are projections and subject to change. Revenue figures marked as placeholders are pending team confirmation.